Aeglea BioTherapeutics Inc. (AGLE) NASDAQ

$1.57 0.02 (1.29%)

Market Cap: $79.16M

As of 05/27/22 04:00 PM EDT. Market closed.

(AGLE)

Aeglea BioTherapeutics Inc. (AGLE) NASDAQ

$1.57 0.02 (1.29%)

Market Cap: $79.16M

As of 05/27/22 04:00 PM EDT. Market closed.

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough ... read more

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. In the second quarter of 2020, the Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO Compensation (Base)
$507,000
CEO Compensation (Total)
$3.84M
URL
Address
.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Full Time Employees
90
CEO Compensation (Base)
$507,000
CEO Compensation (Total)
$3.84M
Address
.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
KEY STATS
Open
$1.58
Previous Close
$1.55
Days Range
$1.47 - $1.59
52 week range
$1.29 - $8.50
Volume
112,507
Avg. Volume (30 days)
435,187
Market Cap
$79.16M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
50,419,822
Open
$1.58
Previous Close
$1.55
Days Range
$1.47 - $1.59
52 week range
$1.29 - $8.50
Volume
112,507
Avg. Volume (30 days)
435,187
Market Cap
$79.16M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
50,419,822

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR AEGLEA BIOTHERAPEUTICS INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
Quinn Anthony G. President & CEO Mar 16, 2022 Buy $2.34 80,079 187,705 550,540 Mar 18, 2022, 06:46 AM
Quinn Anthony G. President & CEO Mar 11, 2022 Buy $2.06 34,777 71,780 363,572 Mar 15, 2022, 06:32 PM
Quinn Anthony G. President & CEO Mar 15, 2022 Buy $1.86 42,417 78,942 473,461 Mar 15, 2022, 06:32 PM
Quinn Anthony G. President & CEO Mar 14, 2022 Buy $1.93 67,472 130,221 431,044 Mar 15, 2022, 06:32 PM
Alspaugh Jonathan Chief Financial Officer Mar 11, 2022 Buy $2.08 75,000 156,000 165,372 Mar 15, 2022, 06:30 PM
Shanafelt Armen Director Dec 10, 2021 Buy $3.65 13,516 49,333 135,315 Dec 13, 2021, 08:41 PM
Shanafelt Armen Director Dec 09, 2021 Buy $3.67 121,799 446,759 121,799 Dec 13, 2021, 08:41 PM
Shanafelt Armen Director Dec 13, 2021 Buy $3.65 14,685 53,600 150,000 Dec 13, 2021, 08:41 PM
Quinn Anthony G. President & CEO Dec 10, 2021 Buy $3.75 10,526 39,473 328,795 Dec 13, 2021, 08:39 PM
Quinn Anthony G. President & CEO Dec 09, 2021 Buy $3.70 43,108 159,500 318,269 Dec 13, 2021, 08:39 PM
Alspaugh Jonathan Chief Financial Officer Dec 09, 2021 Buy $3.72 50,000 186,000 90,372 Dec 13, 2021, 08:37 PM
Alspaugh Jonathan Chief Financial Officer Aug 18, 2021 Buy $6.72 7,200 48,400 40,372 Aug 18, 2021, 05:21 PM
Alspaugh Jonathan Chief Financial Officer Aug 17, 2021 Buy $6.50 23,392 151,985 33,172 Aug 18, 2021, 05:21 PM
Alspaugh Jonathan Chief Financial Officer Aug 16, 2021 Buy $6.37 9,780 62,275 9,780 Aug 18, 2021, 05:21 PM
Quinn Anthony G. President & CEO Apr 30, 2020 Buy $4.75 165,000 783,750 538,469 May 04, 2020, 07:30 AM
Quinn Anthony G. President & CEO Oct 04, 2019 Option Exercise $6.28 18,265 114,689 371,908 Oct 07, 2019, 04:09 PM
Quinn Anthony G. President & CEO Jun 14, 2019 Buy $6.23 5,282 32,913 353,643 Jun 14, 2019, 05:22 PM
Quinn Anthony G. President & CEO Jun 13, 2019 Buy $6.17 14,406 88,836 348,361 Jun 14, 2019, 05:22 PM
Quinn Anthony G. President & CEO Jun 12, 2019 Buy $6.11 12,217 74,705 333,955 Jun 14, 2019, 05:22 PM
Quinn Anthony G. President & CEO May 22, 2019 Buy $6.86 3,809 26,128 321,738 May 22, 2019, 04:55 PM
Quinn Anthony G. President & CEO May 21, 2019 Buy $6.89 13,794 94,981 317,929 May 22, 2019, 04:55 PM
Quinn Anthony G. President & CEO May 20, 2019 Buy $6.55 8,989 58,923 304,135 May 22, 2019, 04:55 PM
Quinn Anthony G. President & CEO Feb 15, 2019 Buy $7.10 719 5,103 277,152 May 17, 2019, 05:04 PM
Quinn Anthony G. President & CEO May 17, 2019 Buy $6.65 6,218 41,335 295,146 May 17, 2019, 05:04 PM
Quinn Anthony G. President & CEO May 16, 2019 Buy $6.83 5,520 37,691 288,928 May 17, 2019, 05:04 PM
Quinn Anthony G. President & CEO May 15, 2019 Buy $6.76 6,256 42,269 283,408 May 17, 2019, 05:04 PM
Quinn Anthony G. President & CEO Feb 06, 2019 Option Exercise $6.18 8,756 54,126 276,433 Feb 08, 2019, 04:15 PM
Quinn Anthony G. President & CEO Dec 07, 2018 Option Exercise $4.37 171,890 751,816 267,677 Dec 10, 2018, 05:40 PM
Quinn Anthony G. President & CEO Aug 15, 2018 Buy $9.13 994 9,075 95,787 Dec 10, 2018, 05:40 PM
Quinn Anthony G. President & CEO Feb 15, 2018 Buy $6.02 2,000 12,040 94,793 Dec 10, 2018, 05:40 PM
Schuchart Aaron Chief Business Officer Sep 27, 2018 Sale $9.50 6,000 57,005 8,400 Sep 28, 2018, 05:11 PM
Schuchart Aaron Chief Business Officer Aug 17, 2018 Option Exercise $3.50 8,500 29,750 8,500 Aug 21, 2018, 04:24 PM
GEORGIOU GEORGE Director Aug 13, 2018 Option Exercise $5.91 37,333 220,784 175,861 Aug 15, 2018, 04:40 PM
Quinn Anthony G. Interim CEO Jul 12, 2018 Option Exercise $6.76 38,866 262,764 92,793 Jul 16, 2018, 09:04 AM
Quinn Anthony G. Interim CEO Jul 11, 2018 Option Exercise $5.46 3,307 18,056 53,927 Jul 13, 2018, 09:05 AM
Novartis Bioventures Ltd 10% Owner May 11, 2018 Sale $10.06 19,550 196,673 2,175,314 May 14, 2018, 04:01 PM
Novartis Bioventures Ltd 10% Owner May 10, 2018 Sale $10.13 22,725 230,204 2,194,864 May 11, 2018, 04:28 PM
Novartis Bioventures Ltd 10% Owner May 09, 2018 Sale $10.11 51,230 517,935 2,217,589 May 11, 2018, 04:28 PM
Novartis Bioventures Ltd 10% Owner May 08, 2018 Sale $10.03 26,557 266,367 2,268,819 May 09, 2018, 04:01 PM
Novartis Bioventures Ltd 10% Owner May 07, 2018 Sale $10.11 15,548 157,190 2,295,376 May 09, 2018, 04:01 PM
Quinn Anthony G. Interim CEO Feb 15, 2018 Option Exercise $5.46 15,211 83,052 50,620 Feb 20, 2018, 12:00 AM
Quinn Anthony G. Interim CEO Dec 08, 2017 Buy $5.07 600 3,039 35,409 Dec 08, 2017, 07:06 PM
Quinn Anthony G. Interim CEO Dec 07, 2017 Buy $4.99 2,800 13,967 34,809 Dec 08, 2017, 07:06 PM
Quinn Anthony G. Interim CEO Dec 06, 2017 Buy $4.92 4,888 24,072 32,009 Dec 08, 2017, 07:06 PM
York Charles N II Chief Financial Officer and VP Dec 01, 2017 Buy $4.59 6,500 29,855 21,287 Dec 05, 2017, 09:07 PM
York Charles N II Chief Financial Officer and VP Aug 15, 2017 Buy $2.52 1,959 4,929 14,787 Dec 05, 2017, 09:07 PM
York Charles N II Chief Financial Officer and VP Feb 15, 2017 Buy $4.28 2,000 8,568 12,828 Dec 05, 2017, 09:07 PM
York Charles N II Chief Financial Officer and VP Aug 15, 2016 Buy $3.99 2,000 7,974 10,828 Dec 05, 2017, 09:07 PM
York Charles N II Chief Financial Officer and VP Dec 05, 2017 Buy $4.76 10,241 48,700 34,787 Dec 05, 2017, 09:07 PM
York Charles N II Chief Financial Officer and VP Dec 04, 2017 Buy $4.97 3,259 16,197 24,546 Dec 05, 2017, 09:07 PM
Quinn Anthony G. Director Dec 04, 2017 Buy $4.98 7,956 39,624 22,056 Dec 05, 2017, 09:04 PM
Quinn Anthony G. Director Dec 01, 2017 Buy $4.53 4,100 18,578 14,100 Dec 05, 2017, 09:04 PM
Quinn Anthony G. Director Dec 05, 2017 Buy $4.93 5,065 24,976 27,121 Dec 05, 2017, 09:04 PM
ORBIMED ADVISORS LLC 10% Owner Feb 21, 2017 Buy $5.36 7,000 37,520 1,469,524 Feb 21, 2017, 05:58 PM
ORBIMED ADVISORS LLC 10% Owner Feb 17, 2017 Buy $5.19 71,800 372,642 1,462,524 Feb 21, 2017, 05:58 PM
ORBIMED ADVISORS LLC 10% Owner Feb 16, 2017 Buy $5.04 30,500 153,720 1,390,724 Feb 21, 2017, 05:58 PM
LILLY ELI & CO 10% Owner Apr 12, 2016 Buy $10.00 500,000 5,000,000 2,568,543 Apr 14, 2016, 06:41 PM
Quinn Anthony Director Apr 12, 2016 Buy $10.00 10,000 100,000 10,000 Apr 12, 2016, 05:10 PM
Novartis Bioventures Ltd 10% Owner Apr 12, 2016 Buy $10.00 300,000 3,000,000 2,310,924 Apr 12, 2016, 05:09 PM
Cox Russell J. Director Apr 12, 2016 Buy $10.00 7,000 70,000 7,000 Apr 12, 2016, 05:06 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
Quinn Anthony G. President & CEO 03/16/2022 187,705
Quinn Anthony G. President & CEO 03/11/2022 71,780
Quinn Anthony G. President & CEO 03/15/2022 78,942
Quinn Anthony G. President & CEO 03/14/2022 130,221
Alspaugh Jonathan Chief Financial Officer 03/11/2022 156,000
Shanafelt Armen Director 12/10/2021 49,333
Shanafelt Armen Director 12/09/2021 446,759
Shanafelt Armen Director 12/13/2021 53,600
Quinn Anthony G. President & CEO 12/10/2021 39,473
Quinn Anthony G. President & CEO 12/09/2021 159,500
Alspaugh Jonathan Chief Financial Officer 12/09/2021 186,000
Alspaugh Jonathan Chief Financial Officer 08/18/2021 48,400
Alspaugh Jonathan Chief Financial Officer 08/17/2021 151,985
Alspaugh Jonathan Chief Financial Officer 08/16/2021 62,275
Quinn Anthony G. President & CEO 04/30/2020 783,750
Quinn Anthony G. President & CEO 10/04/2019 114,689
Quinn Anthony G. President & CEO 06/14/2019 32,913
Quinn Anthony G. President & CEO 06/13/2019 88,836
Quinn Anthony G. President & CEO 06/12/2019 74,705
Quinn Anthony G. President & CEO 05/22/2019 26,128
Quinn Anthony G. President & CEO 05/21/2019 94,981
Quinn Anthony G. President & CEO 05/20/2019 58,923
Quinn Anthony G. President & CEO 02/15/2019 5,103
Quinn Anthony G. President & CEO 05/17/2019 41,335
Quinn Anthony G. President & CEO 05/16/2019 37,691
Quinn Anthony G. President & CEO 05/15/2019 42,269
Quinn Anthony G. President & CEO 02/06/2019 54,126
Quinn Anthony G. President & CEO 12/07/2018 751,816
Quinn Anthony G. President & CEO 08/15/2018 9,075
Quinn Anthony G. President & CEO 02/15/2018 12,040
Schuchart Aaron Chief Business Officer 09/27/2018 57,005
Schuchart Aaron Chief Business Officer 08/17/2018 29,750
GEORGIOU GEORGE Director 08/13/2018 220,784
Quinn Anthony G. Interim CEO 07/12/2018 262,764
Quinn Anthony G. Interim CEO 07/11/2018 18,056
Novartis Bioventures Ltd 10% Owner 05/11/2018 196,673
Novartis Bioventures Ltd 10% Owner 05/10/2018 230,204
Novartis Bioventures Ltd 10% Owner 05/09/2018 517,935
Novartis Bioventures Ltd 10% Owner 05/08/2018 266,367
Novartis Bioventures Ltd 10% Owner 05/07/2018 157,190
Quinn Anthony G. Interim CEO 02/15/2018 83,052
Quinn Anthony G. Interim CEO 12/08/2017 3,039
Quinn Anthony G. Interim CEO 12/07/2017 13,967
Quinn Anthony G. Interim CEO 12/06/2017 24,072
York Charles N II Chief Financial Officer and VP 12/01/2017 29,855
York Charles N II Chief Financial Officer and VP 08/15/2017 4,929
York Charles N II Chief Financial Officer and VP 02/15/2017 8,568
York Charles N II Chief Financial Officer and VP 08/15/2016 7,974
York Charles N II Chief Financial Officer and VP 12/05/2017 48,700
York Charles N II Chief Financial Officer and VP 12/04/2017 16,197
Quinn Anthony G. Director 12/04/2017 39,624
Quinn Anthony G. Director 12/01/2017 18,578
Quinn Anthony G. Director 12/05/2017 24,976
ORBIMED ADVISORS LLC 10% Owner 02/21/2017 37,520
ORBIMED ADVISORS LLC 10% Owner 02/17/2017 372,642
ORBIMED ADVISORS LLC 10% Owner 02/16/2017 153,720
LILLY ELI & CO 10% Owner 04/12/2016 5,000,000
Quinn Anthony Director 04/12/2016 100,000
Novartis Bioventures Ltd 10% Owner 04/12/2016 3,000,000
Cox Russell J. Director 04/12/2016 70,000
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
03/31/2022
12/31/2021
0.38%
1Q
03/31/2022
09/30/2021
0.49%
2Q
03/31/2022
06/30/2021
0.58%
3Q
03/31/2022
03/31/2021
0.60%
4Q
03/31/2022
12/31/2020
23.65%
5Q
03/31/2022
09/30/2020
33.40%
6Q
Load More

Period of Report: 03/31/2022

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
12/31/2021
0.38%
1Q
09/30/2021
0.49%
2Q
06/30/2021
0.58%
3Q
03/31/2021
0.60%
4Q
12/31/2020
23.65%
5Q
09/30/2020
33.40%
6Q
Load More